Heating lyophilised factor VIII does not alter its recognition by specific antibodies

Vox Sanguinis

Volumn 73, Issue 1, 1997, Pages 16-23

  Gilles, J G ^a   Di Giamhattista, M ^b   Laub, R ^b   Saint Remy, Jean Marie R ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Rode Kruis Vlaanderen   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 8; RABBIT ANTISERUM;

ARTICLE; FREEZE DRYING; HEAT TREATMENT; IMMUNOGENICITY; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030742134     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.1997.7310016.x     Document Type: Article

References (19)

1. Brackman HH, Etzel F, Hoffmann P, Egli H The successful treatment of acquired inhibitors against factor VIII Thromb Haemost 1977;38:369.
2. Gomperts E, Stanley J, Church JA, Sakai R, Lemne J: Induction of tolerance to FVIII in a child with a high-uter inhibitor: In vitro and in vivo observations. J Pediatr 1984;104:70.
3. Mariani G, Ghirardini A, Bellocco R, Immune tolerance in hemophilia: Principal results from the international registry. Thromb Haemost 1994;72:155-158.
4. Lakich D, Kazazian HH, Antonarakis SE, Gitschier J: Inversions disrupting the factor VIII gene as a common cause of severe hemophilia A Nature Genet 1993;5:236-241.
5. Naylor JA, Green PM, Rizza CR, Gianelli F: Factor VIII gene explains all cases of haemophilia A. Lancet 1992;340:1066-1067.
6. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JMR, Vermylen J: A higher then expected incidence of factor-VIII inhibitors in multitransfused haemophilia-A patients treated with an intermediate purity pasteurized factor-VIII concentrate. Thromb Haemost 1993;69:115-118.
7. Peerlinck K, Arnout J, DiGiambattista M, Gilles JG, Laub R, Jacquemin M, Saint-Remy JMR, Vermylen J: Factor VIII inhibitors in previously treated hemophilia A patients with a double virus-ubactivated plasma derived factor VIII concentrate. Thromb Haemost 1997;77:80-86.
8. Saint-Remy JMR, Gilles JGG: Variations in antigenicity of factor VIII concentrates: Preclinical evaluation Vox Sang 1996;70:15-18.
9. Gruffin B, Mieklem L, McCann M, James K, Pepper D: The production and characterization of a panel of ten murine monoclonal antibodies to hyman procoagulant factor VIII. Thromb Haemost 1986;55:40-48.
10. Gilles JGG, Arnout J, Vermylen J, Saint-Remy JMR: Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993;82:2452-2461.
11. Van Sniek J, Coulie P: Monoclonal anti-lgG autoantibodies derived from lipopolysaccharideactivated spleen cells of 129 Sv mice. J Exp Med 1982;155:219.
12. Gilles JG, Saint-Remy JMR: Healthy subjects produce both anti-factor VIII and specific antiidiotypic antibodies. J Clin Invest 1994;94:1496-1505.
13. Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantone J, Green D, Hempton JW, Hilgartner MN, Lazarson J, Levin PH, Macmillan CN, more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975;34:869-872.
14. Svendsen L, Brogli M, Lindeberg G, Stocker K: Differentiation of thrombin- and factor Xa-related amidolytic activity in plasma by means of a synthetic thrombin inhibitor. Thromb Res 1984;34:457.
15. Leyte A, Mertens K, Distel B, Evers RE, De Keyzer-Nellen MJM, Groenen-van Dooren MMCL, De Brum J, Pannekoek H, van Mourik JAJA, Verbeet MP: Inhibition of human coagulation factor VIII by monoclonal antibodies. Biochemistry J 1989;263:187-194.
16. Stel HV,Sakariassen KS, Seholte BJ, Veerman ECL van der Kwast TH, de Groot PG, Sixma JJ, van Mourik JA: Characterzation of 25 monoclonal antibodies to factor VIII-von Willebrand factor: Relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium. Blood 1984;63:1408-1415.
17. Scandella D, Timmons L, Mattingly M, Trabold N, Hoyer LW: A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by imnumoblotting Thromb Haemost 1992;67:665-671.
18. macGregor IR, McLaugin LF, McGregor MC, Prowse CV, Pepper DS: No detectable alterations in immunogenecity following terminal severe dry-heat treatment of high-purity factor VIII (Liberate) and factor IX (HP9) concent rates. Vox Sang 1995;69:319-327.
19. Pittman DD, Alderman EM, Tonkinson KN, Wang JH, Gites AR, Kaufman RJ:Biotechnol immunologicul and in vivo functional characterization of B-domain-delected factor VIII Blood 1993;81:2925-2935.